Virtual meeting
Via Zoom
Description
This training will cover evidence-based strategies for initiating buprenorphine treatment within ambulatory care practices. Special attention will be directed towards effective measures that support the transition of patients using illicitly manufactured fentanyl onto prescribed buprenorphine.
NOTE: This training is 60 minutes long; we will stay on the call for an extra 30 minutes after it is scheduled to end for an optional Q&A session.
Intended audience
Medical providers, nurses, social workers, Licensed Alcohol and Drug Counselors (LADC), Certified Alcohol/Drug Counselors (CADC), Community Health Workers (CHW), recovery coaches, counselors, Licensed Mental health Counselors (LMHC), and others working in addiction medicine.
Credits
NOTE: Please read the accreditation information section of the training event page for details and requirements for earning continuing education.
- CME (1.00)
- Nursing (1.00) ; Pharmacology (1.00)
- Social work (1.00)
- LADC (1.00)
- CADC (1.00)
- Recovery coach (1.00)
- LMHC (1.00)
Objectives
1. Describe the prevalence of illicitly manufactured fentanyl in the US drug supply.
2. Explain the major pharmacologic properties of both fentanyl and buprenorphine.
3. Recall at least two "tools" that can help guide the process of starting buprenorphine treatment.
4. Identify at least three medications that have been proven to support management of withdrawal symptoms during the buprenorphine initiation process.
Sponsored by
Boston Medical Center Grayken Center for Addiction TTA, Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
